Boehringer Ingelheim Awarded Contract for Vaccine Bank to Help Protect US Livestock from Foot and Mouth Disease

DULUTH, Ga., July 8, 2020 /PRNewswire/ -- The U.S. Department of Agriculture (USDA) has awarded Boehringer Ingelheim a contract to help supply a vaccine bank that will protect U.S. livestock from foot-and-mouth disease.

The contract calls for Boehringer Ingelheim to create and maintain a strategic reserve of frozen vaccine antigen concentrate that the company could quickly formulate into a vaccine for foot-and-mouth disease (FMD) in the event of an outbreak in the U.S.

The National Animal Vaccine and Veterinary Countermeasures Bank, commonly known as the U.S. vaccine bank, will let the U.S. stockpile veterinary vaccines and other materials to use in the event of an outbreak of a high-impact foreign animal disease.

FMD is a highly contagious viral disease that can affect cattle, pigs, sheep, goats and other animals with divided hooves. It does not affect people. The U.S. eradicated FMD in 1929, but an outbreak could devastate the livestock industry and, consequently, our national food supply, if left unchecked.

"Boehringer Ingelheim has proudly supported the U.S. livestock industry for decades as a leader in animal vaccine technology," said Everett Hoekstra, President of Boehringer Ingelheim Animal Health USA Inc. "Infectious animal diseases can disrupt our food supply, and governments make significant investments to help prevent and prepare for such events."

"As a global leader in the storage and management of FMD vaccine banks, with FMD expertise dating back more than 70 years, Boehringer Ingelheim constantly monitors emerging disease threats," said Steve Boren, Vice President of the U.S. Livestock Business at Boehringer Ingelheim Animal Health.

Veterinarians, researchers and livestock leaders have long worried about the possibility of an outbreak of foot-and-mouth disease in the United States. Congress set aside money in the 2018 Farm Bill for the vaccine bank and other measures to guard against foreign animal disease outbreaks.

The USDA's Animal and Plant Health Inspection Service is responsible for overseeing the National Animal Vaccine and Veterinary Countermeasures Bank. It has more information about its most recent steps to supply the bank here.

About Boehringer Ingelheim Animal Health
Boehringer Ingelheim is the second largest animal health business in the world, with net sales of $4.5 billion (4 billion euros) in 2019 and presence in more than 150 markets.

As the lives of animals and humans are intertwined, our 10,000 global employees are dedicated to enhancing the well-being of both – through science and innovation, as well as through their commitment and passion.

Respect for animals, people and the environment is at the heart of what we do. We develop medicines, services and innovative digital technologies to protect animals from disease and pain. We support our customers in taking care of the health of their animals and protect our communities against life- and society-threatening diseases.

Boehringer Ingelheim Animal Health has a significant presence in the United States, with more than 3,100 employees in places that include Georgia, Missouri, Iowa, Minnesota, New Jersey and Puerto Rico. To learn more, visit www.boehringer-ingelheim.us, www.facebook.com/BoehringerAHUS or www.twitter.com/Boehringer_AH.

About Boehringer Ingelheim
Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives.

Since its founding in 1885, Boehringer Ingelheim has been independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of $21.3 billion (19 billion euros). Our significant investment of over $3.9 billion (3.5 billion euros) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

Media Contacts:

Mark Bixler
Boehringer Ingelheim
Animal Health
U.S. Communications
678-209-3077
[email protected]

SOURCE Boehringer Ingelheim Animal Health USA Inc.

Related Links

https://www.boehringer-ingelheim.us